Letermovir (INN) is an antiviral drug that is being developed for the treatment of cytomegalovirus (CVM) infections. It has been tested in CMV infected patients.
Letermovir (also known as or is a new, efficacious, first-in- class anti-HCMV drug currently being developed for the prevention of HCMV.
Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection. Coming Soon; Congestive Heart Failure Peer Exchange